How to buy Novo Nordisk (NVO) stock from India

Yes, an Indian resident can buy Novo Nordisk — legally, under the RBI's Liberalised Remittance Scheme (LRS). NVO trades on the NYSE as an ADR, but the underlying shares are Danish-domiciled. That single fact rewrites two checklist items: dividend withholding runs through Danish rules, and the $60,000 US estate-tax trap does not bite as it would for a US-domiciled stock. This is the short version.

The 30-second version

• Legal and simple. Buy NVO via any India-facing platform (Vested, INDmoney) or a global broker (Interactive Brokers, Rovia). Whole ADRs or a fractional rupee amount.
• Dividend-payer with a Danish twist. Denmark's statutory withholding is 27%, but the India-Denmark DTAA caps it at 15% for portfolio holders. In practice the BNY Mellon depositary often applies 27% upfront, and you reclaim the 12% excess from Danish tax — slow and broker-dependent.
• India tax: hold more than 24 months and pay 12.5% LTCG (no indexation); sell sooner and pay your slab rate. Section 112, not the friendlier 112A.
• The estate-tax trap most assume applies — doesn't. ADRs of foreign-domiciled issuers are generally treated as having situs in the underlying jurisdiction (Denmark). NVO is not caught by the $60,000 US-situs trap — a real advantage versus US-domiciled rival Eli Lilly.
• If your thesis is "GLP-1," XLV and IHE hold NVO and LLY together — same theme, no single-readout risk.

Quick facts

Can an Indian resident buy it?	Yes — fully legal under the LRS
Ticker / exchange	NVO / NYSE (ADR; underlying Danish-listed)
How	India-facing platform (Vested, INDmoney) or global broker (IBKR, Rovia)
Minimum	A fraction of one ADR
Dividend	Yes; Danish WHT 27% statutory, 15% under India-Denmark DTAA
India tax on gains	12.5% LTCG after 24 months; else slab (Section 112)
US estate-tax risk	Generally not US-situs for ADRs of foreign-domiciled issuers
Annual compliance	Schedule FA every year; Form 67 for reclaimable WHT

How to buy it — 3 steps

1. Open an account and finish KYC. Pick an India-facing platform (Vested, INDmoney) or a global broker (Interactive Brokers, Rovia). File your W-8BEN during onboarding — it certifies your non-US tax status to the depositary and broker. New to this? Start with how to invest in US stocks from India.
2. Fund it via the LRS. Remit from your Indian bank under the LRS (cap: $250,000 per financial year). 20% TCS applies above ten lakh rupees in a year — a creditable prepayment, not a cost. See LRS explained and the LRS and TCS calculator.
3. Place the order. Each NVO ADR represents one Novo Nordisk B share. The ADR trades in the fifty-to-eighty-dollar range after the post-2024 compression, so a whole ADR is affordable, or buy a fractional rupee amount.

The tax that actually matters — and the Danish dividend wrinkle

Two separate events: the dividend while you hold, and the capital gain when you sell.

Dividend. Denmark's statutory WHT on outbound dividends is 27%; the India-Denmark DTAA caps it at 15% for portfolio holders. In a clean flow you would see 15% withheld; in practice, with the BNY Mellon depositary, many Indian brokers see the full 27% deducted at the ADR, with a refund through Skattestyrelsen for the 12% excess — slow, document-heavy, broker-dependent. Whatever is withheld, you claim foreign-tax credit via Form 67 before your ITR. Mechanics in dividend withholding and Form 67. This differs from a US-domiciled payer, where 25% US WHT applies cleanly under the India-US DTAA.

Capital gains. Under Section 112 (foreign shares do not get the Section 112A treatment Indian-listed equity enjoys):

Holding period	Treatment	Rate
24 months or less	Short-term	Your slab rate (up to roughly 30% plus surcharge)
More than 24 months	Long-term	12.5%, no indexation

Worked example. Buy 20 ADRs at $60 when USD/INR is 86 → cost 10,32,000 rupees. Sell 28 months later at $80 when USD/INR is 88 → proceeds 14,08,000 rupees. Taxable gain 3,76,000 rupees; LTCG at 12.5% = 47,000 rupees. The gain is computed in rupees, so a weaker rupee amplifies your reported gain. Model your own with the US capital-gains calculator; full rules in how US stocks are taxed in India.

The estate-tax question — and the Danish advantage

The standard warning for directly-held US stocks is the $60,000 US-situs estate-tax trap: above that threshold, a non-resident's US-situs assets face up to 40% US estate tax with no India-US treaty relief. The technical position for ADRs of foreign-domiciled issuers like NVO is that situs follows the underlying shares — Denmark — not the listing venue. The prevailing read is that NVO ADRs do not trigger the US $60k trap.

This is a real advantage versus US-domiciled Lilly, where the $60k trap applies in full. Indian succession rules still apply, but the 40% US bite that drives planning around AMZN, MSFT, or LLY is materially less of a concern here. Background: the $60,000 estate-tax trap.

Buy the stock, or get Novo Nordisk through an ETF?

If you want…	Best route
A concentrated bet on NVO out-executing Lilly	NVO directly
"GLP-1 will keep growing" exposure	XLV or IHE — holds NVO and LLY together
Broad international developed exposure including NVO	A developed-markets or Europe ETF
Least single-readout risk	A broad healthcare ETF

NVO sits inside healthcare ETFs like XLV and IHE alongside Lilly, which spreads the binary "who wins GLP-1" risk. NVO has a modest weight in broader international indices and is not in QQQ or the S&P 500 (those are US-listing indices). For GLP-1 thematic exposure without picking the winner, a healthcare ETF is usually the cleaner trade. Compare routes in direct stocks vs US ETFs and best US ETFs for Indian investors; broader case in US ETFs for Indians. Direct comparison: how to buy Eli Lilly stock from India.

The business in one screen

What it is: Danish-domiciled pharma with a hundred-year history in insulin and diabetes care. It pioneered the modern GLP-1 era with Ozempic (semaglutide for type-2 diabetes) and Wegovy (same molecule, dosed for obesity), and runs one of the industry's largest peptide-manufacturing footprints. The pipeline centres on CagriSema and amycretin (an oral GLP-1 plus amylin agonist), aimed at restoring efficacy parity with Lilly's tirzepatide.

Bull case	Bear case
GLP-1 franchise scale and global commercial presence	Lilly's tirzepatide showed superior weight-loss in head-to-head trials
Insulin and diabetes legacy: 100+ years of cash-flow stability	CagriSema Phase 3 readouts have been mixed versus expectations
Oral GLP-1 optionality via amycretin and oral semaglutide	PBM pricing pressure and US payer push-back
Danish domicile — no US $60k estate-tax trap for Indian holders	Generic semaglutide as patents roll off in the late 2030s
Manufacturing constraints easing — supply now meeting demand	Valuation compression as growth-leadership narrative shifts to LLY

Exact valuation is in the live widget above — high-quality franchise, no longer the unambiguous GLP-1 leader.

Our take

Verdict: HOLD — still a top-tier diabetes and obesity franchise, but the GLP-1 leadership baton has shifted to Lilly, and the Indian-investor case rests partly on Danish-domicile tax advantages.

• Pioneered the category, no longer leading it. Ozempic and Wegovy created the modern GLP-1 market, and Novo's manufacturing scale remains world-class. But Lilly's tirzepatide has shown superior weight-loss in head-to-head data, and Novo's next-gen response has had merely-okay rather than category-defining readouts.
• Easing supply, tightening pricing. Manufacturing constraints that once justified premium pricing have eased; the next two years are about PBM negotiations and net-price defence more than volume growth. Diabetes legacy keeps cash flows steady, but the growth narrative has migrated to LLY.
• The Danish-domicile angle helps an Indian holder. No US-situs estate exposure, treaty-capped dividend withholding (15% DTAA, often 27% in practice with a reclaim), and a 24-month Section 112 path are net-net friendlier than a comparable US-domiciled name. HOLD reflects a high-quality franchise that no longer earns a premium versus its closest competitor — fine to own, hard to recommend as a new high-conviction add today.

Compliance note. Vested.blog is not a SEBI-registered Research Analyst. The above is an editorial opinion for educational illustration only — not investment advice and not a regulated stock recommendation. Vested.blog is published by Rovia; the publisher and its affiliates may hold positions in stocks discussed. Make your own decisions or consult a SEBI-registered advisor.

Risks to size for

• Competitive intensity from Lilly: tirzepatide's efficacy lead, an aggressive pipeline (retatrutide, orforglipron), and faster manufacturing ramp pose a structural share risk a single name takes on the chin.
• Pipeline binary risk: CagriSema and amycretin readouts move the stock double-digits in a session. A direct holding concentrates that beta in a way an ETF does not.
• Currency and depositary frictions: USD-quoted ADR, DKK underlying, INR spend — two currency legs plus a Danish withholding refund that may or may not deliver. See the rupee-dollar effect.

Two things people forget

• Schedule FA: disclose NVO in Schedule FA of your ITR every year you hold it — even if bought and sold within the year, even at a loss. Non-disclosure carries Black Money Act penalties. Because NVO pays a dividend, you will also typically file Form 67 to claim foreign-tax credit for Danish WHT. Use the Schedule FA helper.
• Position size: a single drug-franchise name is not an index. Size NVO as a high-conviction satellite, not a substitute for a broad healthcare ETF — GLP-1 winner-take-most risk is real.

Bottom line

Buying NVO from India is easy and legal. What needs thought isn't the buying — it's that NVO is a Section-112 capital-gains play (12.5% after 24 months), a Danish-domiciled ADR with treaty-capped dividend withholding (15% per the DTAA, 27% in practice with a reclaim), and a single pharma franchise sharing a category with a tougher competitor in LLY. The upside versus a US-domiciled peer: ADRs of foreign-domiciled issuers are generally not caught by the US $60k estate trap. If your real thesis is GLP-1, a healthcare ETF gives the same exposure without the binary readout risk. Start at the US investing hub.

---

This article is general information, not personalised investment, tax, or legal advice. Rules, rates, and thresholds described here are as of 2026 and can change; verify the current position and consult a qualified advisor before acting.